摘要
本文报告急性脑梗塞260例,其中160例急性脑梗塞应用尿激酶10万~U+N·S100ml,静脉滴注,q12h×10天;100例应用Svate-Ⅲ 2~U+N·S100ml,静脉滴注一次/日×15天,两组同时应用Ca^(++)拮抗剂,稀释疗法及脑细胞赋形剂治疗。结果尿激酶组基愈率为65%,显效率90.63%,总有效率达96.26%,非常显著优于Svate-Ⅲ的51%、75%及89%。结果提示尿激酶治疗急性脑梗塞在注意出血倾向发生时是安全、有效的。
Urokinasum is a dissovle-emloli medicine, which can improve microcirculation. 160 patients with cerebral infarction in acute period treated were observed. Rate of striking effect and total improvement rate were 90. 63% and 96. 26% respectively. Compered with 100 patients controls with Svate- Ⅲ , which rate of striking effect and total improvement rate were 75% and 89% respectively. There were marked differences in striking effect rate and total improvement rate (P<0. 01). The data indicated that effect of this medicine was apparent, safe with little side-effects. UK is suitable for early use.
出处
《脑与神经疾病杂志》
1998年第4期216-218,共3页
Journal of Brain and Nervous Diseases
关键词
尿激酶
急性
脑梗塞
Svate-Ⅲ
治疗
Urokinsum Svate- Ⅲ Acute-infarction initial ictal moter menifestation Dissovle-emloli
